United Therapeutics Corporation $UTHR Holdings Lifted by State of Alaska Department of Revenue

Key Points

• The State of Alaska Department of Revenue increased its stake in United Therapeutics Corporation by 17.0%, now holding 19,532 shares valued at $5.6 million.
• Multiple institutional investors have significantly increased their holdings, with Acadian Asset Management boosting their position by 1,657.8% in the first quarter.
• Analysts are optimistic about United Therapeutics, with a consensus rating of "Moderate Buy" and an average target price increase to $448.14.

State of Alaska Department of Revenue grew its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 17.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,532 shares of the biotechnology company's stock after purchasing an additional 2,840 shares during the period. State of Alaska Department of Revenue's holdings in United Therapeutics were worth $5,612,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Vaughan Nelson Investment Management L.P. bought a new position in shares of United Therapeutics in the first quarter valued at approximately $101,354,000. Nuveen LLC bought a new position in shares of United Therapeutics in the first quarter valued at approximately $83,533,000. Amundi boosted its holdings in shares of United Therapeutics by 198.8% in the first quarter. Amundi now owns 350,193 shares of the biotechnology company's stock valued at $107,635,000 after acquiring an additional 232,988 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of United Therapeutics by 29,415.2% in the first quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock valued at $68,422,000 after acquiring an additional 221,202 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in shares of United Therapeutics by 1,657.8% in the first quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company's stock valued at $55,217,000 after acquiring an additional 169,010 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on UTHR shares. Bank of America increased their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a report on Wednesday, September 10th. Jefferies Financial Group raised their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. UBS Group raised their target price on shares of United Therapeutics from $415.00 to $560.00 and gave the stock a "buy" rating in a report on Thursday, September 4th. Finally, Royal Bank Of Canada assumed coverage on shares of United Therapeutics in a report on Friday. They set an "outperform" rating and a $569.00 target price for the company. Ten research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $448.14.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $432.66 on Monday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $442.01. The company has a market cap of $19.52 billion, a PE ratio of 16.89, a price-to-earnings-growth ratio of 6.60 and a beta of 0.62. The firm has a 50 day simple moving average of $342.90 and a 200 day simple moving average of $314.85.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the previous year, the company earned $5.85 EPS. The firm's quarterly revenue was up 11.7% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $11,356,133.75. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 192,935 shares of company stock worth $73,905,462 in the last 90 days. 10.30% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.